Serum testosterone, dihydrotestosterone, luteinizing hormone and follicle-stimulating hormone versus prostate specific antigen in patients with localized prostate adenocarcinoma who underwent radical prostatectomy. Radioimmunoassays measurements.
Bantis A, Zissimopoulos A, Athanasiadou P, Gonidi M, Agelonidou E, Strataki A, Matthaios D, Tsartsarakis A. Hell J Nucl Med. 2007 Jan-Apr;10(1):56-61.

Body mass index does not predict prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screening.
Hutterer G, Perrotte P, Gallina A. Eur J Cancer. 2007 May;43(7):1180-7. 

Body composition, metabolic syndrome and testosterone in aging men.
Allan CA, Strauss BJ, McLachlan RI. Int J Impot Res. Jun 7 2007.

Bioavailable testosterone should be used for the determination of androgen levels in infertile men.
Ashok S, Sigman M. J Urol. Apr 2007;177(4):1443-1446; quiz 1591.

The association of time of day and serum testosterone concentration in a large screening population.
Crawford ED, Barqawi AB, O'Donnell C, Morgentaler A. BJU Int. Jun 6 2007.

Evaluation of an algorithm for calculation of serum "bioavailable" testosterone (BAT).
Emadi-Konjin P, Bain J, Bromberg IL. Clin Biochem. Nov 2003;36(8):591-596.

Mechanisms for pulsatile regulation of the gonadotropin subunit genes by GNRH1.
Ferris HA, Shupnik MA. Biol Reprod. Jun 2006;74(6):993-998.

Andropause: a quality-of-life issue in older males.
Haren MT, Kim MJ, Tariq SH, Wittert GA, Morley JE. Med Clin North Am. Sep 2006;90(5):1005-1023.

Andropause.
Kevorkian R. Mo Med. Jan-Feb 2007;104(1):68-71; quiz 71.

Andropause: symptom management for prostate cancer patients treated with hormonal ablation.
Thompson CA, Shanafelt TD, Loprinzi CL. Oncologist. 2003;8(5):474-487.